Skip to main content
Article thumbnail
Location of Repository

De novo three-way chromosome translocation 46,XY,t(4;6;21)(p16;p21.1;q21) in a male with cleidocranial dysplasia

By Smita M Purandare, Roberto Mendoza-Londono, Svetlana A Yatsenko, Dobrawa Napierala, Daryl A Scott, Tarek Sibai, Kari Casas, Patrick Wilson, Jiyun Lee, Razia Muneer, Joe C Leonard, Faridali G Ramji, Ralph Lachman, Shibo Li, Pawel Stankiewicz, Brendan Lee and John J Mulvihill

Abstract

Cleidocranial dysplasia (CCD) is an autosomal dominant skeletal dysplasia associated with cranial, clavicular, and dental anomalies. It is caused by mutations in the RUNX2 gene, which encodes an osteoblast-specific transcription factor and maps to chromosome 6p21. We report clinical and molecular cytogenetic studies in a patient with clinical features of CCD including wormian bones, delayed fontanel closure, hypoplastic clavicles and pubic rami, and supernumerary dentition. Additional abnormalities of bone growth and connective tissue, including easy bruisability, scarring, bleeding, joint hypermobility, and developmental delay were also observed. Molecular cytogenetic studies identified a de novo apparently balanced three-way translocation 46,XY,t(4;6;21)(p16;p21.1;q21). Further mapping revealed the breakpoint on 6p21 to be ∼50 kb upstream of exon 1 of the RUNX2 gene, with RUNX2 being intact on the derivative chromosome 6. We hypothesize that the proband's CCD has arisen from disruption of the developmentally regulated gene RUNX2 at the 6p21 breakpoint, due to a position effect mutation which may have altered the expression of the gene. Further studies might unravel a new regulatory element for RUNX2

Topics: Clinical Report
Publisher: Wiley Subscription Services, Inc., A Wiley Company
OAI identifier: oai:pubmedcentral.nih.gov:2663417
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (2001). A natural history of cleidocranial dysplasia.
    2. (1999). CBFA1 mutation analysis and functional correlation with phenotypic variability in cleidocranial dysplasia. Hum Mol Genet 8:2311–2316.
    3. (2006). Cleidocranial dysplasia plus vascular anomalies with 6p21.2 microdeletion spanning RUNX2 and VEGF. Am J Med Genet Part A 140A:398–401.
    4. (2006). Cleidocranial dysplasia.
    5. (2005). Control of RUNX2 isoform expression: The role of promoters and enhancers.
    6. (1999). Discovery:Osf2/Cbfa1, a master gene of bone formation.
    7. (2005). Dysregulation of chondrogenesis in human cleidocranial dysplasia.
    8. (1995). Genetic mapping of cleidocranial dysplasia and evidence of microdeletion in one family. Hum Mol Genet 4:71–75.
    9. (1995). Genetic mapping of the cleidocranial dysplasia (CCD) locus on chromosome band 6p21 to include a microdeletion.
    10. (1997). Missense mutations abolishing DNA binding of the osteoblast-specific transcription factor OSF2/CBFA1 in cleidocranial dysplasia.
    11. (2005). Mutations and promoter SNPs in RUNX2, a transcriptional regulator of bone formation.
    12. (1997). Mutations involving the transcription factor CBFA1 cause cleidocranial dysplasia.
    13. (1993). Pericentric inversion of chromosome 6 in a patient with cleidocranial dysplasia.
    14. (2003). Prenatal diagnosis of a cleidocranial dysplasia-like phenotype associated with a de novo balanced t(2q;6q)(q36;q16) translocation. Ultrasound Obstet Gynecol 22:648–651.
    15. Scherer SW.2005.Holoprosencephalyandcleidocranialdysplasiaina patient due to two position effect mutations: Case report and review of the literature.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.